Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:196-206
doi: 10.1161/CIRCULATIONAHA.107.691378
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maron, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maron, B. J.
Related Collections
Right arrow Hypertrophy
Right arrow Myocardial cardiomyopathy disease
Right arrow Ablation/ICD/surgery
Right arrow CT and MRI
Right arrow CV surgery: other

(Circulation. 2007;116:196-206.)
© 2007 American Heart Association, Inc.


Controversies in Cardiovascular Medicine

Is septal ablation preferable to surgical myomectomy for obstructive hypertrophic cardiomyopathy?

Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy

Barry J. Maron, MD

From the Minneapolis Heart Institute Foundation, Minneapolis, Minn.

Correspondence to Barry J. Maron, MD, Minneapolis Heart Institute Foundation, 920 E 28th St, Ste 60, Minneapolis, MN 55407. E-mail hcm.maron@mhif.org


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
The evolving alcohol septal ablation versus surgical myectomy controversy represents a crossroad in the management of obstructive hypertrophic cardiomyopathy (HCM). Indeed, in this now polarized debate within the cardiovascular community, between the traditional and established (ie, surgery) and the new and percutaneous (ie, ablation), much is at stake for the HCM patient population. Furthermore, this issue has become increasingly important given the visibility recently afforded the pathophysiological significance and frequency of left ventricular (LV) outflow gradients in this disease.1,2

Response by Fifer p 206

In the course of this discussion, I will vigorously defend surgery as the primary treatment of choice when outflow obstruction (gradient ≥50 mm Hg at rest or with physiological exercise) produces heart failure symptoms refractory to maximal medical management (New York Heart Association functional classes III and IV).3,4 To this purpose, I will rely on the 50-year experience and substantial body of evidence available in HCM, as well as my own personal extensive association with and work in this disease spanning >30 years and several hundred publications—neither as a surgeon or interventional cardiologist nor with any particular allegiance to either discipline. The message expressed herein is prosurgery, but it is by no means antiablation, for this treatment modality has proved useful (although with a selective role) in the management of HCM.


*    Surgical Septal Myectomy
 
Historical Context
When surgical septal myectomy (Table 1) was initially introduced in the early 1960s at several North American and European centers, it was regarded as revolutionary and has subsequently stood the test of time. . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
B. J. Maron, M. S. Maron, E. D. Wigle, and E. Braunwald
The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy.
J. Am. Coll. Cardiol., July 14, 2009; 54(3): 191 - 200.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
T. Matsushita, T. Kawase, E. Tsuda, and K. Kawazoe
Apicoaortic conduit for the dilated phase of hypertrophic obstructive cardiomyopathy as an alternative to heart transplantation
Interactive CardioVascular and Thoracic Surgery, February 1, 2009; 8(2): 232 - 234.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
N. Parakh and B. Bhargava
Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: The Joys Are Brief: The Results Are Lasting
J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 74 - 74.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
V. L. Fernandes, C. Nielsen, S. F. Nagueh, A. E. Herrin, C. Slifka, J. Franklin, and W. H. Spencer III
Follow-Up of Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy: The Baylor and Medical University of South Carolina Experience 1996 to 2007
J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 561 - 570.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. S. Adabag, B. J. Maron, E. Appelbaum, C. J. Harrigan, J. L. Buros, C. M. Gibson, J. R. Lesser, C. A. Hanna, J. E. Udelson, W. J. Manning, et al.
Reply
J. Am. Coll. Cardiol., September 9, 2008; 52(11): 969 - 970.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Olivotto, S. R. Ommen, M. S. Maron, F. Cecchi, and B. J. Maron
Reply
J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1234 - 1235.
[Full Text] [PDF]